Abstract
Rationale
Recommended medication prescribing hierarchies for adult attention-deficit hyperactivity disorder (ADHD) vary between different guideline committees. Few trials directly compare competing ADHD medications in adults and provide little insight for clinicians making treatment choices.
Objective
The objective of this study was to assess comparative benefits and harms of competing medications for adult ADHD using indirect comparison meta-analysis.
Materials and methods
Eligible studies were English-language publications of randomized controlled trials comparing ADHD drugs to placebo. Data sources were electronic bibliographic databases, Drugs@FDA, manufacturer data, and reference lists. Two reviewers independently abstracted data on design, internal validity, population, and results. Benefits and harms were compared between drug types using indirect comparison meta-regression (ratio of relative risks).
Results
Twenty-two placebo-controlled trials were included (n = 2,203). Relative benefit of clinical response for shorter-acting stimulants, primarily immediate release methylphenidate, was 3.26 times greater than for patients taking longer-acting stimulants (95% CI 2.03, 5.22) and 2.24 times greater than for patients taking longer-acting forms of bupropion (95% CI 1.23, 4.08). Immediate release methylphenidate is also the only drug shown to reduce ADHD symptoms in adults with substance abuse disorders. Neither non-stimulants nor longer-acting stimulants reduced adverse effects compared to shorter-acting stimulants. Key gaps in evidence were academic, occupational, social functioning, cardiovascular toxicity, and longer-term outcomes, influences of ADHD subtype and/or comorbidities, and misuse/diversion of the drugs.
Conclusions
Current best evidence supports using immediate release methylphenidate as first-line treatment for most adults with ADHD.
Similar content being viewed by others
References
Anonymous (2001) Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews CRD Report Number 4 (2nd edition). York, UK, NHS Centre for Reviews and Dissemination
Asherson P (2005) Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 5:525–539
Barkley RA (2004) Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27:233–260
Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T et al (2006) A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59:829–835
Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR (2005) Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 21:195–206
Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF (2005) A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 100:1868–1874
Chou R, Fu R, Huffman LH, Korthuis PT (2006) Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses [see comment]. Lancet 368:1503–1515
Dodson WW (2005) Pharmacotherapy of adult ADHD. J Clin Psychol 61:589–606
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test [see comment]. BMJ 315:629–634
Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31:140–149
Food and Drug Administration (2006a) Drug Safety and Risk Management Advisory Committee Meeting, vol 2006
Food and Drug Administration (2006b) Pediatric Advisory Committee, vol 2006
Food and Drug Administration Drugs@FDA, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D (2001) Current methods of the third U.S. Preventive Services Task Force. Am J Prev Med 20:21–35
Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P et al (2005) The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 47:565–572
Kessler RC, Adler L, Barkley RA, Biederman J, Conners CK, Demler O et al (2006) The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry 163:716–723
Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK (2004) Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 34:973–982
Levin ED, Conners CK, Silva D, Canu W, March J (2001) Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 9:83–90
Levin F, Evans S, Brooks D, Kalbag A, Garawi F, Nunes E (2006) Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 81:137–148
Levin FR, Evans SM, Brooks DJ, Garawi F (2007) Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87:20–29
Matza LS, Paramore C, Prasad M (2005) A review of the economic burden of ADHD. Cost Eff Resour Alloc 3:5
McDonagh MS, Peterson K (2006) Drug class review of pharmacologic treatment of ADHD, vol 2006
McGough JJ, Smalley SL, McCracken JT, Yang M, Del’Homme M, Lynn DE, Loo S (2005) Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 162:1621–1627
Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ et al (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120
Montano B (2004) Diagnosis and treatment of ADHD in adults in primary care. J Clin Psychiatry 65(Suppl 3):18–21
Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z (1999) A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder [comment]. Aust N Z J Psychiatry 33:494–502
Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED (2005) Bupropion SR in adults with ADHD: A short-term, placebo-controlled trial. Neuropsychiatric Disease and Treatment 1:245–251
Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK (2007) A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93–101
Riccio CA, Wolfe M, Davis B, Romine C, George C, Lee D (2005) Attention deficit hyperactivity disorder: manifestation in adulthood. Arch Clin Neuropsychol 20:249–269
Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N et al (2002) Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 10:286–294
Secnik K, Swensen A, Lage MJ (2005) Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics 23:93–102
Song F, Altman DG, Glenny A-M, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 326:472
Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434–443
Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J et al (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693–695
Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Gerard K et al (2001) Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder [comment]. Arch Gen Psychiatry 58:775–782
Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J et al (2005) A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456–463
Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ARG (2007) Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 61:1380–1387
Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux P-Y, Secnik K (2004) Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 35:346.e341–349
Terrin NSCH, Lau J (2005) In an empirical evaluation of funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 58:894–901
Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK et al (2006) Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 11:625–639
Weiss M, Hechtman L, The Adult ARG (2006) A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 67:611–619
Wender PH, Reimherr FW, Wood D, Ward M (1985) A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 142:547–552
Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J et al (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158:282–288
Wilens TE, Haight BR, Horrigan JP et al (2005) Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 57:793–801
Acknowledgments
The authors thank Sujata G. Thakurta, MPA:HA, Research Assistant 2 for her substantial contribution to this work in the areas of administrative, technical, and material support.
Funding for this systematic review and meta-analysis was supported by the Drug Effectiveness Review Project (DERP). The authors retained full and independent control of the design of this meta-analysis; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the final manuscript. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors have no financial interest in any company that makes or distributes any of the products reviewed in this report.
Author information
Authors and Affiliations
Corresponding author
Additional information
Financial disclosures
None of the authors or the person named in the Acknowledgments section have any financial interest in any company that makes or distributes the products reviewed in this report.
Rights and permissions
About this article
Cite this article
Peterson, K., McDonagh, M.S. & Fu, R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology 197, 1–11 (2008). https://doi.org/10.1007/s00213-007-0996-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-007-0996-4